NexCAR19: India’s first indigenous CAR T-cell therapy

ForumIAS announcing GS Foundation Program for UPSC CSE 2025-26 from 18th June. Click Here for more information.

Source– This post on NexCAR19: India’s first indigenous CAR T-cell therapy is based on the article “President of India Launches India’s First Home-Grown Gene Therapy for Cancer” published in “PIB” on 4th April 2024.

Why in the News?

The President of India recently launched India’s first indigenous anti-cancer CAR-T cell therapy, NexCAR19, at IIT Bombay.

What is NexCAR19?

Source- Indian Express
AboutIt is India’s first indigenously-developed CAR-T cell therapy.
Developed byIIT Bombay, Tata Memorial Centre and ImmunoACT
PurposeDesigned to target cancer cells carrying the CD19 protein.
Recommended forPeople with B-cell lymphomas who didn’t respond to standard treatments like chemotherapy, leading to relapse or recurrence of the cancer.
Treatment Process1. Patient donates blood at a transfusion centre. The blood goes to the lab, where the T-cells are genetically modified.
2. In a week to 10 days, these cells return to the clinic for patient reinfusion.
Recovery1. Recovery typically occurs within two weeks after one cycle of the treatment.
2. In the study conducted, approximately 70% of patients respond to the treatment, with variations between leukemia and lymphoma cases. About 50% of these responsive patients achieve a complete response.
SignificanceIndia is one of the first developing countries to have its indigenous CAR-T and gene therapy platform.

What is ImmunoAct?

1. About– Founded in 2018 as a spin-off from IIT-Bombay, ImmunoACT leads the way in pioneering India’s development of its first indigenous Cell & Gene Therapy.

2. Mission– To ensure affordable access to innovative autologous CAR-T cell therapies.

UPSC Syllabus- Science & Technology

Print Friendly and PDF